<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-437
Date of Submission: 2025-01-01

This report was submitted by a Physician from Phillips, Payne and Morrison Medical Center concerning patient ANON-PX-8095. The subject is a 32-year-old male with a significant medical history including atrial fibrillation, asthma, hypertension, anxiety. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Atorvastatin administered via the Intramuscular route at a dosage of 52mg, initiated on 2024-10-10 for Hypercholesterolemia and discontinued on 2024-12-27.

On approximately 2024-12-25, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Maculopapular Rash, Headache, Angioedema. The Maculopapular Rash was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed single and advised center. The current patient status regarding this symptom is 'Not Recovered'. The Headache was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Angioedema was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Gas she risk answer. Thousand one experience station. Commercial management finish certainly.</data>
report_id: ADR-2025-437
report_date: '2025-01-01'
patient_details:
  patient_id: ANON-PX-8095
  gender: Male
  relevant_history:
  - atrial fibrillation
  - asthma
  - hypertension
  - anxiety
  age_at_reaction: 32
suspected_drugs:
- drug_name: Atorvastatin
  dosage: 52mg
  route_of_administration: Intramuscular
  start_date: '2024-10-10'
  indication_for_use: Hypercholesterolemia
  end_date: '2024-12-27'
adverse_reactions:
- symptom_name: Maculopapular Rash
  onset_date: '2024-12-25'
  severity: Mild
  outcome: Not Recovered
  intervention_required: true
  intervention_details: Prescribed single and advised center.
- symptom_name: Headache
  onset_date: '2024-12-25'
  severity: Mild
  outcome: Recovered
  intervention_required: false
- symptom_name: Angioedema
  onset_date: '2024-12-25'
  severity: Moderate
  outcome: Not Recovered
  intervention_required: false
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Negative dechallenge
reporting_facility: Phillips, Payne and Morrison Medical Center
reporter_type: Physician
notes: Gas she risk answer. Thousand one experience station. Commercial management
  finish certainly.
